Tianjin Unode Laboratory of Basic Medical Urology, Tianjin Institute of Urology, Department of Urology, the Second Hospital of Tianjin Medical University, PR China.
Acta Histochem. 2011 Sep;113(5):514-8. doi: 10.1016/j.acthis.2010.05.004. Epub 2010 Jul 2.
Aurora-A is an oncogenic serine/threonine kinase, which plays important roles in tumorigenesis, development and chemoresistance of human cancers. The aim of the study was to detect the expression of Aurora-A gene in bladder cancer tissues and analyze its association with prognosis of bladder cancer patients. RT-PCR was performed to detect the expression of Aurora-A mRNA in 20 cases of bladder cancer and corresponding non-tumor tissue samples. Immunohistochemistry was performed to detect the localization of Aurora-A protein in 96 cases of bladder cancer tissue samples. Associations between Aurora-A protein expression and clinico-pathological factors or survival of bladder cancer patients were statistically analyzed. It was found that the expression levels of Aurora-A mRNA in bladder cancer tissues (1.08±0.24) were significantly higher than those in corresponding non-tumor tissues (0.22±0.07; P<0.01). Moreover, immunohistochemical staining results showed the localization of Aurora-A protein to be mainly located in the cytoplasm of bladder cancer cells. High levels of Aurora-A protein expression were correlated with pathological stage (P=0.007), lymph node metastasis (P=0.014) and venous invasion (P=0.008), but not with other factors including age, gender, tumor grade and recurrence of superficial cancer. Patients with high expression levels of Aurora-A protein showed lower disease-free and overall survival rates than those with low expression levels (P=0.0072 and 0.0009, respectively). Univariate and multivariate analysis of prognostic factors in bladder cancer patients indicated that Aurora-A expression was an independent unfavorable prognostic factor (hazard ratio: 0.673; 95% confidence interval: 0.388-0.912; P<0.001). Our study suggests that overexpression of Aurora-A gene may play an important role in the progression of bladder cancer and that Aurora-A expression is an independent factor for predicting the prognosis of bladder cancer in patients.
Aurora-A 是一种致癌的丝氨酸/苏氨酸激酶,在人类癌症的发生、发展和化疗耐药中发挥重要作用。本研究旨在检测膀胱癌组织中 Aurora-A 基因的表达,并分析其与膀胱癌患者预后的关系。采用 RT-PCR 检测 20 例膀胱癌及相应非肿瘤组织样本中 Aurora-A mRNA 的表达。采用免疫组织化学法检测 96 例膀胱癌组织样本中 Aurora-A 蛋白的定位。统计分析 Aurora-A 蛋白表达与膀胱癌患者临床病理因素及生存的关系。结果发现,膀胱癌组织中 Aurora-A mRNA 的表达水平(1.08±0.24)明显高于相应非肿瘤组织(0.22±0.07;P<0.01)。此外,免疫组化染色结果显示 Aurora-A 蛋白主要定位于膀胱癌细胞质中。Aurora-A 蛋白高表达与病理分期(P=0.007)、淋巴结转移(P=0.014)和静脉侵犯(P=0.008)有关,而与其他因素如年龄、性别、肿瘤分级和表浅癌复发无关。Aurora-A 蛋白高表达患者的无病生存率和总生存率均低于低表达患者(P=0.0072 和 0.0009)。膀胱癌患者预后因素的单因素和多因素分析表明,Aurora-A 表达是独立的不良预后因素(危险比:0.673;95%置信区间:0.388-0.912;P<0.001)。本研究表明,Aurora-A 基因的过表达可能在膀胱癌的进展中起重要作用,Aurora-A 表达是预测膀胱癌患者预后的独立因素。